BACKGROUND: To analyze the related factors affecting the prognosis of pancreatic carcinoma with portal system invasion. METHODS: We retrospectively analyzed the clinical data of 118 patients with portal venous system invasion in Beijing Chaoyang Hospital between January 2011 and December 2018. Only patients with borderline resectable pancreatic cancer were included in this study. Borderline pancreatic cancer was defined according to NCCN (The National Comprehensive Cancer Network) guidelines. All patients underwent surgical treatment combined with vascular resection and reconstruction. The prognosis was evaluated according to the follow-up results, and the related risk factors for prognosis were analyzed. The survival curve was drawn by Kaplan-Meier method, and the survival rate was compared by log-rank test. Multivariate Cox regression was used to analyze the prognostic factors. RESULTS: In our research, all of 126 patients were successfully completed the operations. Complications occurred in 29.7% of patients and perioperative death in 4.0%. A total of 118 patients were followed up and the followed-up rate was 97.5% (118/121). The overall 1-year, 2-year and 3-year survival rates were 49.2%, 27.1% and 19.8%, And the median survival time was 20 months. Multivariate analysis showed that preoperative CA19-9 (RR 1.449, 95% CI: 1.053-1.994), N status (RR 2.533, 95% CI: 1.337-4.798), degree of tumor differentiation (RR 1.592, 95% CI: 1.064-2.381) and venous invasion depth (RR 2.03, 95% CI: 1.504-2.758) were independent risk factors for the prognosis. CONCLUSIONS: The long-term prognosis of pancreatic carcinoma patients with portal system invasion is poor. The venous invasion depth is an independent risk factor for the prognosis of pancreatic carcinoma with portal system invasion, the deeper of venous invasion, the worse the prognosis, and poorly differentiated tumors have the worst prognosis. Other independent risk factors included N status and the preoperative CA19-9. Those may help with patients' selection for different treatment protocols. 2021 Gland Surgery. All rights reserved.
BACKGROUND: To analyze the related factors affecting the prognosis of pancreatic carcinoma with portal system invasion. METHODS: We retrospectively analyzed the clinical data of 118 patients with portal venous system invasion in Beijing Chaoyang Hospital between January 2011 and December 2018. Only patients with borderline resectable pancreatic cancer were included in this study. Borderline pancreatic cancer was defined according to NCCN (The National Comprehensive Cancer Network) guidelines. All patients underwent surgical treatment combined with vascular resection and reconstruction. The prognosis was evaluated according to the follow-up results, and the related risk factors for prognosis were analyzed. The survival curve was drawn by Kaplan-Meier method, and the survival rate was compared by log-rank test. Multivariate Cox regression was used to analyze the prognostic factors. RESULTS: In our research, all of 126 patients were successfully completed the operations. Complications occurred in 29.7% of patients and perioperative death in 4.0%. A total of 118 patients were followed up and the followed-up rate was 97.5% (118/121). The overall 1-year, 2-year and 3-year survival rates were 49.2%, 27.1% and 19.8%, And the median survival time was 20 months. Multivariate analysis showed that preoperative CA19-9 (RR 1.449, 95% CI: 1.053-1.994), N status (RR 2.533, 95% CI: 1.337-4.798), degree of tumor differentiation (RR 1.592, 95% CI: 1.064-2.381) and venous invasion depth (RR 2.03, 95% CI: 1.504-2.758) were independent risk factors for the prognosis. CONCLUSIONS: The long-term prognosis of pancreatic carcinoma patients with portal system invasion is poor. The venous invasion depth is an independent risk factor for the prognosis of pancreatic carcinoma with portal system invasion, the deeper of venous invasion, the worse the prognosis, and poorly differentiated tumors have the worst prognosis. Other independent risk factors included N status and the preoperative CA19-9. Those may help with patients' selection for different treatment protocols. 2021 Gland Surgery. All rights reserved.
Authors: R Ravikumar; C Sabin; M Abu Hilal; A Al-Hilli; S Aroori; G Bond-Smith; S Bramhall; C Coldham; J Hammond; R Hutchins; C Imber; G Preziosi; A Saleh; M Silva; J Simpson; G Spoletini; D Stell; J Terrace; S White; S Wigmore; G Fusai Journal: Br J Surg Date: 2017-08-22 Impact factor: 6.939
Authors: N Volkan Adsay; Olca Basturk; Michelle Bonnett; Nihal Kilinc; Aleodor A Andea; Jining Feng; Mingxin Che; Michael R Aulicino; Edi Levi; Jeanette D Cheng Journal: Am J Surg Pathol Date: 2005-06 Impact factor: 6.394
Authors: G M Fuhrman; S D Leach; C A Staley; J C Cusack; C Charnsangavej; K R Cleary; A K El-Naggar; C J Fenoglio; J E Lee; D B Evans Journal: Ann Surg Date: 1996-02 Impact factor: 12.969
Authors: Matthew M Rochefort; Jacob S Ankeny; Brian E Kadera; Graham W Donald; William Isacoff; Zev A Wainberg; O Joe Hines; Timothy R Donahue; Howard A Reber; James S Tomlinson Journal: Ann Surg Oncol Date: 2013-08-14 Impact factor: 5.344
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Mashaal Dhir; Gautam K Malhotra; Davendra P S Sohal; Nicholas A Hein; Lynette M Smith; Eileen M O'Reilly; Nathan Bahary; Chandrakanth Are Journal: World J Surg Oncol Date: 2017-10-10 Impact factor: 2.754